02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
17:02 , May 23, 2019 |  BC Extra  |  Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
19:54 , May 13, 2019 |  BC Extra  |  Financial News

May 13 Financial Quick Takes: Biotech trio update IPO plans, plus Vedanta, TreeFrog

Peloton, Ideaya, Bicycle set IPO terms  Peloton Therapeutics Inc. (Dallas, Texas) was among three biotechs amending proposed IPOs on NASDAQ. The HIF2A company plans to sell 9.4 million shares at $15-$17. If priced at the...
22:11 , May 9, 2019 |  BC Extra  |  Company News

Management tracks: Akebia, Sangamo, Bicycle

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) said SVP and CMO Rita Jain will step down, effective June 17, to pursue other opportunities. She will be succeeded by Steven Burke, who was SVP and CMO...
21:10 , May 9, 2019 |  BioCentury  |  Finance

Cortexyme’s first-day pop leads IPO quartet amid choppy market

Despite unsettled market conditions, a foursome of biotechs priced their IPOs within their proposed ranges ahead of first-day trading Thursday and helped push the year-to-date tally of money raised in public market debuts well ahead...
22:06 , May 7, 2019 |  BC Extra  |  Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU  The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
19:37 , May 6, 2019 |  BC Extra  |  Company News

May 6 Company Quick Takes: Esperion, BioMarin, WuXi AppTec, Axsome, Harbour BioMed/CTTQ, GW, Adynxx

FDA accepts Esperion NDAs for LDL-C-lowering indications  Esperion Therapeutics Inc. (NASDAQ:ESPR) gained $5 (12%) to $48.24 on Monday after FDA accepted for review a pair of NDAs for bempedoic acid (ETC-1002) and a bempedoic acid/ezetimibe...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
22:26 , Apr 1, 2019 |  BioCentury  |  Finance

Backing Cambridge's AI boom

After raising £150 million ($196 million) in its latest fund, Cambridge Innovation Capital will be keeping an eye on how artificial intelligence and machine learning technology can be applied to the life science sector. CIC...